A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
מצבים רפואיים
Advanced Urothelial Carcinoma · Oral Drug Administration · Open Label
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Contact: Principal Investigator (Terry Friedlander, MD)Yale Cancer Center, New Haven, Connecticut, United States
Contact: Principal Investigator (Daniel Petrylak, MD)Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Jaime R Merchan, MD MMSc)The University of Chicago Medicine, Chicago, Illinois, United States
Contact: Principal Investigator (Randy Sweis, MD)Mass General Cancer Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Xin Gao, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Joaquim Bellmunt, MD, Ph.D.)Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Principal Investigator (Matthew Galsky, MD)Memorial Slone Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Gopa Iyer, MD)UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Matthew Milowsky, MD)The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Shilpa Gupta, MD)Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact: Principal Investigator (Benjamin Garmezy, MD)Houston Methodist Cockrell Center for Advanced Therapeutics, Houston, Texas, United States
Contact: Principal Investigator (Patrick Prath, MD)
מובילי המחקר
Gopa Iyer, MD
Principal Investigator
Memorial Slone Kettering